Lantern Pharma Inc. financial data

Symbol
LTRN on Nasdaq
Location
Dallas, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 437% % -56%
Debt-to-equity 29% % 162%
Return On Equity -126% % -121%
Return On Assets -97% % -90%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11,184,423 shares 3.7%
Common Stock, Shares, Outstanding 11,040,219 shares 2.4%
Entity Public Float $44,285,965 USD -16%
Common Stock, Value, Issued $1,104 USD 2.4%
Weighted Average Number of Shares Outstanding, Basic 10,833,393 shares 0.65%
Weighted Average Number of Shares Outstanding, Diluted 10,833,393 shares 0.65%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $13,038,826 USD -15%
General and Administrative Expense $6,633,305 USD 15%
Operating Income (Loss) $19,672,131 USD 7.2%
Net Income (Loss) Attributable to Parent $18,920,421 USD 0.9%
Earnings Per Share, Basic -1 USD/shares 1.1%
Earnings Per Share, Diluted -1 USD/shares 1.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $8,389,486 USD 3.5%
Marketable Securities, Current $3,973,090 USD -80%
Assets, Current $13,461,005 USD -55%
Property, Plant and Equipment, Net $35,977 USD -26%
Operating Lease, Right-of-Use Asset $93,090 USD -68%
Other Assets, Noncurrent $36,738 USD 0%
Assets $13,626,810 USD -55%
Liabilities, Current $4,039,972 USD 12%
Operating Lease, Liability, Noncurrent $13,524 USD -75%
Liabilities $4,039,972 USD 9.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax $40,333 USD
Retained Earnings (Accumulated Deficit) $89,070,838 USD -27%
Stockholders' Equity Attributable to Parent $9,586,838 USD -64%
Liabilities and Equity $13,626,810 USD -55%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,375,610 USD -43%
Net Cash Provided by (Used in) Financing Activities $54,716 USD
Net Cash Provided by (Used in) Investing Activities $3,239,331 USD
Common Stock, Shares Authorized 25,000,000 shares 0%
Common Stock, Shares, Issued 11,040,219 shares 2.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,133,477 USD 68%
Deferred Tax Assets, Valuation Allowance $17,772,997 USD 42%
Deferred Tax Assets, Gross $17,779,128 USD 42%
Operating Lease, Liability $93,954 USD -68%
Payments to Acquire Property, Plant, and Equipment $1,159 USD -48%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $18,854,824 USD 0.65%
Lessee, Operating Lease, Liability, to be Paid $97,673 USD -69%
Operating Lease, Liability, Current $93,954 USD -52%
Lessee, Operating Lease, Liability, to be Paid, Year Two $54,744 USD -12%
Lessee, Operating Lease, Liability, to be Paid, Year One $54,744 USD -73%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3,719 USD -84%
Deferred Tax Assets, Operating Loss Carryforwards $9,353,936 USD 27%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1,000,000 shares 0%
Operating Lease, Payments $54,000 USD 20%
Additional Paid in Capital $98,616,239 USD 1.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $4,061 USD 19%
Deferred Tax Assets, Net of Valuation Allowance $6,131 USD 59%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%